Blood Test Flags Mantle Cell Lymphoma Relapse Before PET-CT
A recent study suggests that a blood test may be more effective than PET-CT scans in predicting relapses in patients with mantle cell lymphoma after CAR T-cell therapy. The blood test identified relapses a median of 6.5 months earlier than PET-CT scans in a small cohort of patients. Researchers advocate for the blood test's use in detecting minimal residual disease, although they caution that further studies are needed to validate its routine application over PET-CT scans.
- ▪The study involved 37 patients treated with brexucabtagene autoleucel at Stanford University.
- ▪In 15 of 18 patients who relapsed, the blood test identified relapse a median of 6.5 months before PET-CT scans.
- ▪Patients with detectable minimal residual disease had significantly worse progression-free survival compared to those without.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/blood-test-flags-mantle-cell-lymphoma-relapse-before-pet-ct-2026a1000hla?src=rss |
| Publication time | Wed, 27 May 2026 17:53:48 EDT |
| Retrieval time | 2026-05-27T22:08:05.906Z |
| Last seen | 2026-05-27T22:08:05.906Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | CkfsBpNOSS_b |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
A blood test following CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL) appears to do a better job than PET-CT scans at predicting which patients have poor prognoses, a small, retrospective, real-world study finds. In 15 of 18 patients who relapsed, the blood test identified relapse a median of 6.5 months before PET/CT did. “The data from our study supports utilizing this blood test to detect minimal residual disease, and it adds value to PET scans,” said lead author Matthew J. Frank, MD, PhD, in an interview with Medscape Medical News. “We see molecular relapse below the threshold of what a PET-CT scan can show.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
